Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040779 · ClinicalTrials.gov registry record · Phase 3
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 273
- Enrollment target
NCT02040779 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 273 participants.
The verdict
NCT02040779, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 273 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a Breath-Actuated Inhaler (BAI); or a matching BAI placebo, in a 1:1:1 ratio after a 14- to 21-day run-in period. Participants and investigators will remain blinded to randomized treatment assignment during the study
Interventions
- DRUG albuterol/salbutamol
- DRUG Beclomethasone dipropionate breath-actuated inhaler
- DRUG Placebo breath-actuated inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2013-12-26 |
| Est. Completion | 2014-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040779
The ClinicalTrials.gov registry entry for NCT02040779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which albuterol/salbutamol is the first listed.
NCT02040779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02040779 about?
NCT02040779 is a clinical study titled "A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma". This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a Breath-Actuated Inhaler (BAI); or a matching BAI placebo, in a 1:1:1 ratio after ...
What is the current status of trial NCT02040779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 273 participants. The study started on 2013-12-26. Estimated completion is 2014-12-24.
What interventions are being tested in trial NCT02040779?
The interventions under investigation include: albuterol/salbutamol (DRUG), Beclomethasone dipropionate breath-actuated inhaler (DRUG), Placebo breath-actuated inhaler (DRUG).
Who is sponsoring clinical trial NCT02040779?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.